PeptiDream (TSE:4587): Assessing Valuation After New IL-17 Oral Candidate and Alnylam siRNA Milestone [Yahoo! Finance]
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Yahoo! Finance
preclinical siRNA delivery milestone with Alnylam, giving investors fresh data to reassess long term expectations. See our latest analysis for PeptiDream. Despite these clinical and partnership milestones, sentiment around PeptiDream has been cautious. The latest share price is ¥1,664.5 and the year-to-date share price return of negative 33.87 percent has contributed to a one-year total shareholder return of negative 35.23 percent. This suggests that long term optimism has yet to fully translate into renewed momentum. If PeptiDream's progress has you thinking more broadly about innovation in drug development, you might also want to explore healthcare stocks for other potential opportunities in the healthcare space. Yet with revenue growing, losses narrowing and the share price still trading at a steep discount to analyst targets, is PeptiDream quietly undervalued, or is the market already baking in the next leg of growth? With PeptiDream last closing at ¥1,664.5 against a na
Show less
Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- Here's Why Alnylam Pharmaceuticals (ALNY) Surged in Q3 [Yahoo! Finance]Yahoo! Finance
- What PeptiDream (TSE:4587)'s New Oral IL-17 Program and RNAi Milestone Mean For Shareholders [Yahoo! Finance]Yahoo! Finance
- Breyer Capital Expands Healthcare & Life Sciences Team With Appointment of Dr. Bret Bostwick as Venture Advisor [Yahoo! Finance]Yahoo! Finance
- Alnylam's Manufacturing Expansion and Extra-Hepatic RNAi Delivery Could Be A Game Changer For Alnylam Pharmaceuticals (ALNY) [Yahoo! Finance]Yahoo! Finance
- PeptiDream and Alnylam Announce Achievement of Key Milestone in siRNA Conjugate Discovery Collaboration Demonstrating Peptide-Ligand Mediated Targeted siRNA Delivery to Specific Extrahepatic Tissues [Yahoo! Finance]Yahoo! Finance
ALNY
Earnings
- 10/30/25 - Beat
ALNY
Sec Filings
- 12/11/25 - Form 8-K
- 12/3/25 - Form 8-K
- 12/1/25 - Form 4
- ALNY's page on the SEC website